Young Whang, MD
Hematology & Oncology · Chapel Hill, NCNPI 1285796615
Payments from drug & device makers
Across 81 payments — averaging $4410.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Clovis Oncology, Inc.$220K
- Amgen$45K
- Pharmaand GmbH$41K
- Novartis$34K
- Janssen Research & Development, LLC$8K
- Astellas Pharma Global Development$8K
- plus $2K from 1 others
What the payments were for
- Consulting fees$9,560100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Clovis Oncology, Inc. | 53 | $220,157 |
| Amgen | 4 | $44,811 |
| Pharmaand GmbH | 10 | $40,548 |
| Novartis | 5 | $34,179 |
| Janssen Research & Development, LLC | 5 | $8,060 |
| Astellas Pharma Global Development | 3 | $7,979 |
| Telix Pharmaceuticals | 1 | $1,500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUCCIX$3,000
How this compares
$357,234 in reported general payments places this provider in the 80th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 121 | $1,595,789 |
| XtandiEnzalutamide | 34 | $447,106 |
| Abiraterone Acetate | 92 | $102,877 |
| OrgovyxRelugolix | 18 | $45,821 |
| EliquisApixaban | 31 | $17,981 |
| Gabapentin | 37 | $836 |
| Prednisone | 135 | $681 |
| Tamsulosin Hcl | 18 | $426 |
| Prochlorperazine Maleate | 17 | $233 |
| Potassium Chloride | 14 | $189 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $157 |
| Dexamethasone | 25 | $121 |
| Levothyroxine Sodium | 19 | $113 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $41 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Chapel Hill
- Joshua ZeidnerChapel Hill$11.2M
- Jared WeissChapel Hill$7.3M
- Autumn McReeChapel Hill$5.5M
- Christopher DittusChapel Hill$4.7M
- Eben LichtmanChapel Hill$3M
- Brandi ReevesChapel Hill$2.7M
- Jonathan SerodyChapel Hill$1.6M
- William WoodChapel Hill$1.1M
- Juneko Grilley OlsonChapel Hill$1M
- Nigel KeyChapel Hill$872K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.